Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
205–2000. The public version of the
complaint can be accessed on the
Commission’s Electronic Document
Information System (EDIS),¹ and
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,

General information concerning the
Commission may also be obtained by
accessing its Internet server at United
States International Trade Commission
(USITC) at USITC.² The public record
for this investigation may be viewed on
the Commission’s Electronic Document
Information System (EDIS) at EDIS.³

Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.

SUPPLEMENTARY INFORMATION: The
Commission has received a complaint and a
submission pursuant to section
210.8(b) of the Commission’s Rules of
Practice and Procedure filed on behalf of
Draeger Medical Systems, Inc. on
August 29, 2013. The complaint alleges
violations of section 337 of the Tariff
Act of 1930 (19 U.S.C. 1337) in the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain thermal support devices for
infants, infant incubators, infant
warmers and components thereof. The
complaint names as respondent Atom
Medical International, Inc. of Japan. The
complainant requests that the
Commission issue a limited exclusion
order; cease and desist orders; and a
bond upon respondents’ alleged
infringing products during the 60-day
Presidential review period pursuant to
19 U.S.C. 1337(f).

Proposed respondents, other
interested parties, and members of the
public are invited to file comments, not
to exceed five (5) pages in length,
inclusive of attachments, on any public
interest issues raised by the complaint
or section 210.8(b) filing. Comments
should address whether issuance of the
relief specifically requested by the
complainant in this investigation would
affect the public health and welfare in the
United States, competitive
conditions in the United States
eeconomy, the production of like or
directly competitive articles in the
United States, or United States
consumers.

In particular, the Commission is
interested in comments that:
(i) Explain how the articles
potentially subject to the requested
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the requested remedial
orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or third
defendants have the capacity to
replace the volume of articles
potentially subject to the requested
exclusion order and/or a cease and
desist order within a commercially
reasonable time; and
(v) explain how the requested
remedial orders would impact United
States consumers.

Written submissions must be filed no
gerater than by close of business, eight
calendar days after the date of
publication of this notice in the Federal
Register. There will be further
opportunities for comment on the
public interest after the issuance of any
final initial determination in this
investigation.

Persons filing written submissions
must file the original document
electronically on or before the
deadlines stated above and submit 8 true
paper copies to the Office of the Secretary
by noon the next day pursuant to section
210.4(f) of the Commission’s Rules of
Practice and Procedure (19 CFR
210.4(f)). Submissions should refer to
the docket number (“Docket No. 2976”)
in a prominent place on the cover page
and/or the first page. (See Handbook for
Electronic Filing Procedures, Electronic
Filing Procedures). Persons with
questions regarding filing should
contact the Secretary (202–205–2000).

Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR § 201.6.

¹Electronic Document Information System
²United States International Trade
³Electronic Document Information System

INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–494 and 496
(Final)]

Frozen Warmwater Shrimp from
Indonesia and Thailand; Termination of
Investigations

AGENCY: United States International
Trade Commission.

ACTION: Notice.

SUMMARY: On August 19, 2013, the
Department of Commerce published
notices in the Federal Register of
negative final determinations of
subsidies in connection with the subject
investigations concerning Indonesia (78
FR 50379) and Thailand (78 FR 50383).
Accordingly, pursuant to section
207.40(a) of the Commission’s Rules of
Practice and Procedure (19 CFR
207.40(a)), the countervailing duty
investigations concerning frozen
warmwater shrimp from Indonesia and
Thailand (Investigation Nos. 701–TA–
494 and 496 (Final)) are terminated.

DATES: Effective Date: August 19, 2013.

FOR FURTHER INFORMATION CONTACT:
Edward Petronzio (202–205–3176),
Office of Investigations, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436.

Hearing-impaired individuals are
advised that information on this matter
can be obtained by contacting the
Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office of
the Secretary at 202–205–2000.

General information concerning the

¹Handbook for Electronic Filing Procedures: 
²Electronic Document Information System
Commission may also be obtained by accessing its internet server (http://www.usitc.gov). The public record for these investigations may be viewed on the Commission’s electronic docket (EDIS) at http://edis.usitc.gov.

Authority: These investigations are being terminated under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 201.10 of the Commission’s rules (19 CFR 201.10).

By order of the Commission.


Lisa R. Barton,
Acting Secretary to the Commission.

[FR Doc. 2013–21725 Filed 9–5–13; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application; Clinical Supplies Management, Inc.

Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this notice is published that on July 22, 2013, Clinical Supplies Management, Inc., 342 42nd Street South, Fargo, North Dakota 58103, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Sufentanil (9740), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance with the sole purpose of packaging, labeling, and distributing to customers which are qualified clinical sites, conducting FDA-approved clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with D listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 7, 2013.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: August 29, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–21735 Filed 9–5–13; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration; United States Pharmacopeial Convention

By Notice dated May 22, 2013, and published in the Federal Register on May 30, 2013, 78 FR 32457, United States Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, Maryland 20852, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cathinone (1235)</td>
<td>I</td>
</tr>
<tr>
<td>Methaqualone (2565)</td>
<td>I</td>
</tr>
<tr>
<td>Lysergic acid diethylamide (7315)</td>
<td>I</td>
</tr>
<tr>
<td>Marihuana (7360)</td>
<td>I</td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td>I</td>
</tr>
<tr>
<td>4-Methyl-2,5-dimethoxymethamphetamine (7395)</td>
<td>I</td>
</tr>
<tr>
<td>3,4-Methylenedioxyamphetamine (7400)</td>
<td>I</td>
</tr>
<tr>
<td>Codeine-N-oxide (9053)</td>
<td>I</td>
</tr>
<tr>
<td>Difenoxin (9168)</td>
<td>I</td>
</tr>
<tr>
<td>Morphone-N-oxide (9307)</td>
<td>I</td>
</tr>
<tr>
<td>Norlevorphanol (9634)</td>
<td>I</td>
</tr>
<tr>
<td>Amphetamine (1100)</td>
<td>II</td>
</tr>
<tr>
<td>Methamphetamine (1105)</td>
<td>II</td>
</tr>
<tr>
<td>Phenmetrazine (1631)</td>
<td>II</td>
</tr>
<tr>
<td>Methylenedioxymethamphetamine (1724)</td>
<td>II</td>
</tr>
<tr>
<td>Mephobarbital (2125)</td>
<td>II</td>
</tr>
<tr>
<td>Pentobarbital (2270)</td>
<td>II</td>
</tr>
<tr>
<td>Secobarbital (2315)</td>
<td>II</td>
</tr>
<tr>
<td>Glutethimide (2550)</td>
<td>II</td>
</tr>
<tr>
<td>Phencyclidine (7471)</td>
<td>II</td>
</tr>
<tr>
<td>4-Anilino-N-phenethyl-4-piperidine (8333)</td>
<td>II</td>
</tr>
<tr>
<td>Phenylacetone (8561)</td>
<td>II</td>
</tr>
<tr>
<td>Alphaprodine (9015)</td>
<td>II</td>
</tr>
<tr>
<td>Anileridine (9020)</td>
<td>II</td>
</tr>
<tr>
<td>Codeine (9041)</td>
<td>II</td>
</tr>
<tr>
<td>Cocaine (9050)</td>
<td>II</td>
</tr>
<tr>
<td>Dihydrocodeine (9120)</td>
<td>II</td>
</tr>
<tr>
<td>Oxycodeone (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Hydromorphone (9150)</td>
<td>II</td>
</tr>
<tr>
<td>Diphenoxylate (9170)</td>
<td>II</td>
</tr>
</tbody>
</table>